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Abstract
Background: Atopobium vaginae and Gardnerella vaginalis are major markers for bacterial vaginosis. We aimed to
determine the MIC and MBC range of the broad-spectrum anti-infective and antiseptic dequalinium chloride for 28
strains, belonging to 4 species of the genus Atopobium, i.e. A. vaginae, A. minutum, A. rimae and A. parvulum.
Methods: The MIC was determined with a broth microdilution assay.
Results: The MIC and MBC for Atopobium spp. for dequalinium chloride ranged between < 0.0625 and 2 μg/ml.
Conclusions: This study demonstrated that dequalinium chloride inhibits and kills clinical isolates of A. vaginae at
concentrations similar to those of clindamycin and lower than those of metronidazole.
Background
Bacterial vaginosis (BV) is a polymicrobial condition
whereby the lactobacilli dominated vaginal microflora is
overgrown by anaerobes [1], such as Gardnerella vagina-
lis and Atopobium vaginae [2]. BV is the most common
cause of vaginal complaints among women of childbear-
ing age [3].
At the moment there are two recommended therapies
for BV, oral metronidazole or vaginal clindamycin [4],
both with one-month cure rates of 60-90% [5,6]. The
recurrence rate is high, about 30-50% of the women
have a relapse within 2-3 months and 50-70% within 6
to 12 months [3,5,6]. Moreover, resistance of BV-asso-
ciated anaerobic bacteria to metronidazole (1%) versus
17% clindamycin resistance at baseline, and 53% clinda-
mycin resistance after therapy has been reported [7]. In
particular, it has been shown that A. vaginae can be
metronidazole resistant [8-10].
Because both clinical and microbiological efficacy of
the current antibiotic treatment of BV with metronida-
zole, other 5-nitro-imidazoles and clindamycin are not
completely satisfactory, with a high recurrence rate of
vaginosis [3,5-9], alternative treatments, such as the
topical application of broad spectrum anti-infectives and
antiseptics, could offer a solution to bypass possible
antibiotic resistance.
One such antiseptic is dequalinium chloride, for which
the broad microbicidal activity against aerobic and anae-
robic bacteria as well as yeasts has been demonstrated
previously [11], and for which clinical efficacy and safety
in the treatment of BV and other vaginal infections has
been shown [12-14].
The aim of this study was to determine the Minimal
Inhibition Concentration (MIC) and Minimal Bacterici-
dal Concentration (MBC) of DQC for strains of the
genus Atopobium.
Methods
Bacterial strains
Three strains of A. vaginae (CCUG 44258, CCUG 44125
and CCUG 38953T) and one strain each of A. minutum
(CCUG 31167), A. rimae (CCUG 31168) and A. parvu-
lum (CCUG 32760) were obtained from the Culture
Collection of the University of Göteborg, Sweden
(CCUG). All other strains were clinical vaginal isolates
obtained during studies between 2003 and 2010
(Table 1), and isolated after anaerobic culture (at 37°C
for minimum 3 days) on Colombia agar (Becton Dickin-
son (BD), Erembodegem, Belgium), Schaedler agar (BD)
or Tryptic Soy Agar (BD) supplemented with 5% sheep
blood. All strains were identified by 16S rRNA gene
sequencing. Bacteroides fragilis ATCC 25285T was
obtained from the CCUG.
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Broth microdilution assay
A 10,240 μg/ml stock solution of DQC was prepared by
dissolving 102.4 mg DQC (Analysis by Medinova AG,
Zurich, Switzerland) in 10 ml HPLC water. DQC was
dissolved by sonication (Labsonic 1510, B. Brauer, Mel-
sungen, Germany) during 5 minutes at 150 W and incu-
bation in a warm water bath (37°C) for 2 hours.
A serial dilution series ranging from 512 μg/ml to
0.0625 μg/ml DQC was used and tested in duplicate.
Brucella Broth (BD), supplemented with vitamin K (1
μg/ml), hemin (5 μg/ml) and laked horse blood (5%) was
prepared [10]. The different Atopobium spp. and strains
were plated onto Colombia agar (BD) and cultured for 72
hours in an anaerobic chamber (BugBox, LedTechno,
Heusden-Zolder, Belgium) at 37°C. The Brucella Broth
was pre-reduced, prior to use, for 2 hours in the anaero-
bic chamber at 37°C. Every cultured strain was suspended
in physiological water until a 1 McFarland density
(3 × 108 cfu/ml) was obtained, 1 ml of this suspension
was centrifuged for 5 minutes at 7,000 g, and 900 μl of
the supernatans was removed. In the anaerobic chamber,
at 37°C, the 100 μl of remaining bacterial suspension was
added to 5 ml pre-reduced Brucella Broth, yielding a
final load of 6 × 106 cfu/ml, and homogenized.
For each six strains, two 96-well microtiterplates (Axy-
gen, San Francisco, Ca) were used. Plate 1.1 contained
concentrations of 512 μg/ml to 8 μg/ml of DQC in rows
A to G and no antibiotic in row H. Plate 1.2 contained
4 μg/ml to 0.0625 μg/ml in rows A to G and no antibio-
tic in row H. Per strain, two columns of the two 96-well
plates were filled with 100 μl of the bacterial suspension
in Brucella broth per well.
The inoculated plates were incubated anaerobically at
37°C and read after 48 and after 72 hours.
The MIC endpoint was defined as the lowest concen-
tration of DQC that inhibited visible growth of the test
Table 1 Values of MIC and MBC of DQC belonging to 4 species of the genus Atopobium
Test No. Species Strain MIC (μg/ml) MBC (μg/ml)
ST1 Atopobium vaginae CCUG 44125 0.25 0.25
ST2 Atopobium rimae CCUG 31168 1 1
ST3 Atopobium vaginae FB101-3 0.5 0.5
ST4 Atopobium vaginae FB106b < 0.0625 < 0.0625
ST5 Atopobium vaginae VMF0914COL43 < 0.0625 < 0.0625
ST6 Atopobium vaginae VMF0914COL13 < 0.0625 < 0.0625
ST7 Atopobium vaginae VMF0907COL23 < 0.0625 < 0.0625
ST8 Atopobium vaginae PB2003/009-T1-4 < 0.0625 < 0.0625
ST9 Atopobium vaginae PB2003/017-T1-2 < 0.0625 < 0.0625
ST10 Atopobium vaginae BVS067 < 0.0625 < 0.0625
ST11 Atopobium vaginae CCUG 44258 0.0625 0.0625
ST12 Atopobium vaginae FB145-BA-14A < 0.0625 < 0.0625
ST13 Atopobium vaginae FB106B 0.0625 0.0625
ST14 Atopobium vaginae FB158-CNA-2C < 0.0625 < 0.0625
ST15 Atopobium vaginae FB160-CNAB-7A < 0.0625 < 0.0625
ST16 Atopobium vaginae FB160-CNAB-7 < 0.0625 < 0.0625
ST17 Atopobium vaginae FB130-CNAB-2aD 0.5 0.5
ST18 Atopobium vaginae FB010-06 < 0.0625 < 0.0625
ST19 Atopobium vaginae CCUG 38953T < 0.0625 < 0.0625
ST20 Atopobium vaginae FB106C 0.0625 0.0625
ST21 Atopobium vaginae FB101-3C < 0.0625 < 0.0625
ST22 Atopobium vaginae BVS068 0.5 0.5
ST23 Atopobium parvulum VMF1313W43 2 2
ST24 Atopobium parvulum VMF1620W23 2 2
ST25 Atopobium parvulum CCUG 32760 1 1
ST26 Atopobium minutum CCUG 31167 2 2
ST27 Atopobium vaginae FB101-2 < 0.0625 < 0.0625
ST28 Atopobium vaginae PB2003/189-T1-4 < 0.0625 < 0.0625
DQC: dequalinium chloride; MBC: Minimal Bactericidal Concentration; MIC: Minimal Inhibitory Concentration
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isolate. Brownish, dark red wells were considered as
wells without growth and clear and light red wells were
considered as wells with growth (Figure 1).
For plates 1.1 and 1.2, a volume of 25 μl of each well
was plated onto a Colombia agar plate (i.e. solid med-
ium without DQC) to confirm the presence or absence
of growth and to determine the MBC. These culture
plates were incubated for 72 hours in the anaerobic
chamber at 37°C.
In addition, the MICs of A. vaginae CCUG 44258,
CCUG 44125 and CCUG 38953T and B. fragilis ATCC
25285T were tested for clindamycin and metronidazole
using the broth microdilution assay under the same
conditions, to validate the MIC determination approach
used here.
Results
The MIC- and MBC-values of the 28 Atopobium strains
for DQC are shown in Table 1. The MIC and MBC
range of DQC was determined as < 0.0625-2 μg/ml with
an MIC90-value of 2 μg/ml.
All wells that were determined to contain bacterial
growth (based on a light, clear red colour of the growth
medium in the well), and that were cultured on solid
medium without DQC, showed growth on the solid
medium. All wells for which no growth could be
observed (based on a dark, brownish red colour of the
growth medium in the well) and that had been cultured
on solid medium without DQC, showed no growth on
solid medium. This indicates that the MIC values are
similar to the MBC values, i.e. not only growth was
inhibited at the MIC-values, as determined by growth in
microtiterplate broth, but also cells were killed, as no
growth could be obtained when culturing 25 μl of the
broth from the wells were no growth was observed, on
solid media without DQC.
The MICs of A. vaginae CCUG 44258, 44125 and
38953T for clindamycin and metronidazole were compar-
able to those reported in other studies [8,15] (Table 2).
The MIC of B. fragilis ATCC 25285T for metronidazole
was similar to that reported previously [15] (Table 2).
Discussion
Petersen et al. (2002) assessed the therapeutic efficacy of
10 mg DQC in a study population of 121 patients with
various vaginal infections (bacterial vaginosis, fluor vagi-
nalis, vulvo-vaginal candidiasis, trichomoniasis), by mon-
itoring the clinical symptoms, the vaginal pH and the
number of lactobacilli. A positive effect on the restora-
tion of the vaginal ecosystem and good tolerability was
observed, with a limited number of adverse events
(5.8%) [13]. In a recent multicentre study (15 centres in
5 countries), comprising 321 women with BV, rando-
mized to receive either DQC (n = 164) or vaginal clin-
damycin cream (n = 157), Weissenbacher et al. [14]
found vaginal DQC tablets to be equally effective as
vaginal clindamycin cream and to be well tolerated with
no systemic safety concerns.
Together with the broad antibacterial activity of DQC
against various BV-associated microorganisms, i.e.
Figure 1 MIC-testing of DQC in microtiterplate broth format.
MIC: Minimal Inhibitory Concentration, DQC: dequalinium chloride.
Table 2 Comparison of Atopobium vaginaeisolates and Bacteroides fragilistype strain MIC-values (μg/ml) for
clindamycin and metronidazole
Atopobium vaginae CCUG 44258 Atopobium vaginae CCUG 44125 Atopobium vaginae
CCUG 38953T
Bacteroides fragilis
ATCC 25285T
Metronidazole [this study]a 32 128 32 1
Metronidazole [15]b 4 8 16 1
Metronidazole [10]a NT NT > 32 NT
Clindamycin [this study]a < 0.0625 < 0.0625 < 0.0625 < 0.0625
Clindamycin [8]c < 0.016 < 0.016 < 0.016 NT
Clindamycin [16]a, * NT NT NT ≤ 0.25 - > 16
MIC: Minimal Inhibitory Concentration; NT: Not tested
a: CLSI broth microdilution, b: Agar dilution method, c: E-test
* Range based on the MICs of 232 clinical isolates of B. fragilis (the type strain was not included)
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Gardnerella vaginalis, Bacteroides spp. and Prevotella
spp., as shown in previous studies [11,12], our findings
for A. vaginae DQC susceptibility add to the value of
DQC as an alternative treatment for BV and vaginal
infections.
The color change of the broth, which we observed
when bacterial growth was absent and which was useful
to determine the MIC-value, has not been previously
mentioned in other publications using the same method.
Possibly, it can be explained by the effect of living
respectively dead bacteria on the laked horse blood in
the broth.
Conclusions
We conclude that DQC inhibits and kills clinical isolates
of A. vaginae at concentrations similar to clindamycin
and lower than metronidazole [8,15].
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